Your browser doesn't support javascript.
loading
CA 15-3 prognostic biomarker in SARS-CoV-2 pneumonia.
Ros-Lucas, José Antonio; Pascual-Figal, Domingo Andrés; Noguera-Velasco, José Antonio; Hernández-Vicente, Álvaro; Cebreiros-López, Iria; Arnaldos-Carrillo, María; Martínez-Ardil, Isabel M; García-Vázquez, Elisa; Aparicio-Vicente, Mario; Solana-Martínez, Elena; Ruiz-Martínez, Sheyla Yolany; Fernández-Mula, Laura; Andujar-Espinosa, Rubén; Fernández-Suarez, Beatriz; Sánchez-Caro, Maria Dolores; Peñalver-Mellado, Carlos; Ruiz-López, Francisco José.
Afiliação
  • Ros-Lucas JA; Pneumology Service, Clinical University Hospital Virgen de La Arrixaca, Murcia, Spain. jalucas@ucam.edu.
  • Pascual-Figal DA; IMIB- Arrixaca, Murcia, Spain. jalucas@ucam.edu.
  • Noguera-Velasco JA; Catholic University Murcia (UCAM), Murcia, Spain. jalucas@ucam.edu.
  • Hernández-Vicente Á; IMIB- Arrixaca, Murcia, Spain.
  • Cebreiros-López I; Cardiology Service, Clinical University Hospital Virgen de La Arrixaca, , Murcia, Spain.
  • Arnaldos-Carrillo M; University of Murcia (UMU), Murcia, Spain.
  • Martínez-Ardil IM; National Center for Cardiovascular Research (CNIC), Madrid, Spain.
  • García-Vázquez E; CIBER Cardiovascular, Murcia, Spain.
  • Aparicio-Vicente M; Clinical Laboratory Service, Clinical University Hospital Virgen de La Arrixaca, Murcia, Spain.
  • Solana-Martínez E; University of Murcia (UMU), Murcia, Spain.
  • Ruiz-Martínez SY; Clinical Laboratory Service, Clinical University Hospital Virgen de La Arrixaca, Murcia, Spain.
  • Fernández-Mula L; Clinical Laboratory Service, Clinical University Hospital Virgen de La Arrixaca, Murcia, Spain.
  • Andujar-Espinosa R; Family and Community Medicine, Murcia Health Service, Murcia, Spain.
  • Fernández-Suarez B; University of Murcia (UMU), Murcia, Spain.
  • Sánchez-Caro MD; Internal Medicine, Infectious Diseases Section, Clinical University Hospital Virgen de La Arrixaca, Murcia, Spain.
  • Peñalver-Mellado C; Pneumology Service, Clinical University Hospital Virgen de La Arrixaca, Murcia, Spain.
  • Ruiz-López FJ; Pneumology Service, Clinical University Hospital Virgen de La Arrixaca, Murcia, Spain.
Sci Rep ; 12(1): 6738, 2022 04 25.
Article em En | MEDLINE | ID: mdl-35469047
ABSTRACT
The severity of lung involvement is the main prognostic factor in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Carbohydrate antigen 15-3 (CA 15-3), a marker of lung damage and fibrosis, could help predict the prognosis of SARS-CoV-2 pneumonia. This was a retrospective and observational study. CA 15-3 was analyzed in the blood samples of patients consecutively admitted for SARS-CoV-2 pneumonia and whose blood samples were available in the biobank. Other prognostic markers were also measured (interleukin 6 [IL6], C-reactive protein [CRP], D-dimer, troponin T, and NT-ProBNP). The occurrence of in-hospital complications was registered, including death, the need for medical intensive care, and oxygen therapy at discharge. In this study, 539 patients were recruited (54.9% men, mean age 59.6 ± 16.4 years). At admission, the mean concentrations of CA 15-3 was 20.5 ± 15.8 U/mL, and the concentration was correlated with male sex, older age, and other severity markers of coronavirus disease of 2019 (COVID-19) (IL6, CRP, D-dimer, troponine T, and NT-ProBNP). CA 15-3 levels were higher in patients who died (n = 56, 10.4%) (35.33 ± 30.45 vs. 18.8 ± 12.11, p < 0.001), who required intensive medical support (n = 78, 14.4%; 31.17 ± 27.83 vs. 18.68 ± 11.83; p < 0.001), and who were discharged with supplemental oxygen (n = 64, 13.3%; 22.65 ± 14.41 vs. 18.2 ± 11.7; p = 0.011). Elevated CA 15-3 levels (above 34.5 U/mL) were a strong predictor of a complicated in-hospital course, in terms of a higher risk of death (adjusted odds ratio [OR] 3.74, 95% confidence interval [CI] 1.22-11.9, p = 0.022) and need for intensive care (adjusted OR 4.56, 95% CI 1.37-15.8) after adjusting for all other risk factors. The degree of lung damage and fibrosis evaluated in terms of CA 15-3 concentrations may allow early identification of the increased risk of complications in patients with SARS-CoV-2 pneumonia.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia / COVID-19 Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Sci Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia / COVID-19 Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Sci Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha